基于前药物的肝脏向输送:被动和积极的方法
Jiaqi Chen1, Yingrui Yao1, Xiaoran Mao1
1Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Journal of drug targeting
|July 29, 2024
概括
针对肝脏的前期药物通过使用被动和主动向策略来提高治疗效率并减少肝脏疾病的副作用. 未来的研究应该优化药物设计和向效率,以获得临床成功.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝脏是主要的药物点,但像NAFLD和HCC这样的肝脏疾病给全球健康带来了挑战.
- 目前的治疗方法缺乏特异性,导致效率低于最佳,副作用增加.
- 非酒精性脂肪肝疾病 (NAFLD) 和肝细胞癌 (HCC) 是严重的健康问题.
研究的目的:
- 审查针对肝脏的前药物设计的进展.
- 专注于被动和积极的向策略,以改善治疗结果.
- 为开发有效的肝脏向疗法提供见解.
主要方法:
- 在主要的科学数据库 (PubMed,科学网等) 进行系统的文献搜索. ) 的情况.
- 专注于向机制,包括增强透性和保留 (EPR) 效应和瘤微环境.
- 包括通过特定的传送器和受体进行主动准.
主要成果:
- 被动向利用EPR效应和瘤特征进行药物丰富.
- 主动向利用特定的配体来结合肝脏表面受体以实现精确的传递.
- 成功的例子包括小分子,,抗体和纳米粒子作为载体.
结论:
- 针对肝脏的前期药物显著提高治疗疗效,减少副作用.
- 未来的工作需要平衡向策略和优化临床使用药物设计.
- 开发新的向分子和了解肝脏特定受体是关键.
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
36
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
36
Carrier-Mediated Transport
319
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
319
Drug Delivery: Overview
281
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
281
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


